ACRO | A Pioneer in Biomaterials for Regenerative Medicine

Company Overview

A Pioneer in Biomaterials for Regenerative Medicine

Established in 2014, ACRO Biomedical Co., Ltd. is a biotechnology company focused on developing and manufacturing advanced biomaterial-based medical devices for tissue engineering and regenerative medicine. Utilizing proprietary supercritical carbon dioxide (scCO₂) extraction technology, ACRO Biomedical efficiently removes cells, lipids, and non-collagenous proteins from animal tissues while preserving natural collagen scaffolds. These high-quality biological scaffolds are applied in wound care, orthopedics, dentistry, ophthalmology, cardiovascular and neural surgery, and aesthetic microsurgery.

The company’s flagship product, ABCcolla® Collagen Ophthalmic Matrix, has been approved by Taiwan’s Ministry of Health and Welfare for ophthalmic use. To date, ACRO Biomedical holds 93 global patents and has received 42 medical device approvals across multiple countries, including the United States (FDA), India, Singapore, and several others—with international certifications continuously expanding.

Looking ahead, ACRO Biomedical is committed to advancing whole-organ engineering for heart, liver, and kidney applications by developing decellularized organ scaffolds for in vivo recellularization. Through continuous innovation and clinical application, the company aims to shape the future of regenerative medicine.

ABCcolla® Collagen Matrix

ABCcolla® Collagen Matrix is a sterile, bioresorbable wound dressing derived from porcine collagen and manufactured via supercritical CO₂ decellularization. The dressing retains the collagen scaffold’s native triple helix structure, promoting cell proliferation, granulation, and epithelialization. Its high porosity enables efficient exudate absorption and maintains a moist environment to support healing. The matrix is flexible, easy to handle, and completely bioabsorbable within 7–14 days, eliminating the need for removal. No crosslinking agents are used in the production.

ABCcolla® Bone Graft

ABCcolla® Collagen Bone Graft is a decellularized native porcine bone graft material prepared by supercritical CO₂ extraction technology, which is composed of native porcine collagen and bone matrix that are comparable to the human bone matrix. ABCcolla® Collagen Bone Graft is intended for filling and augmentation of bone voids or gaps during orthopedic surgeries. It facilitates cell attachment and improves bone regeneration and neovascularization. During the healing process, ABCcolla® Collagen Bone Graft gradually resorbs and is replenished by new bone.

ABCcolla® ADM Scaffold

ABCcolla® ADM Scaffold is a decellularized porcine collagen dermal matrix developed using patented supercritical CO₂ technology. It effectively absorbs wound exudates and maintains a moist healing environment, supporting tissue regeneration. The product is TFDA- and FDA 510(k)-approved, and was honored with the 21st National Innovation Award for its micro-particle ADM application in medical devices.